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ABSTRACT 
Sheppard A. McKenzie IV:  Local and Systemic Inflammatory Responses in  
Gingivitis Subjects:  Clinical Trial of Topical Triclosan 
 
(Under direction of David Paquette, DMD,MPH, DMSc; Salvador Nares, DDS, PhD; 
James Beck, PhD, MS) 
 
 
The objectives of this randomized clinical trial (RCT) were to evaluate the local 
pharmacodynamic effects of triclosan dentifrice on GCF concentrations of inflammatory 
mediators in subjects with moderate plaque-induced gingivitis, and to measure systemic 
inflammatory mediators and document trends in levels.   Gingivitis subjects were 
randomized for: 1)triclosan dentifrice; 2)placebo bid over four weeks. GCF analyses of 
inflammatory mediators were performed on days 1, 8, 15, 22 and 29 (pre-dosing and 
post-dosing). Serum analyses of inflammatory mediators were performed each visit.  IL-
1β levels were significantly suppressed in the triclosan group short-term.  The data 
indicate consistent short term reductions in local inflammatory mediators when using the 
triclosan dentifrice (in particular IL-1β and Rank-L (p<0.05).  There were no differences 
in levels of serum inflammatory mediators over the course of 29 days.  Nevertheless, the 
levels of CRP in this population were elevated to the range that confers moderate risk for 
future cardiovascular disease. 
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LOCAL INFLAMMATORY RESPONSE TO TOPICAL 
APPLICATION OF TRICLOSAN 
 
ABSTRACT 
Triclosan is a broad spectrum antimicrobial agent that has been shown to reduce 
dental plaque, gingivitis and calculus.  The primary objective of this study was to 
evaluate the local pharmacodynamic effects of 0.3% Triclosan/copolymer dentifrice on 
gingival crevicular fluid (GCF) concentrations of inflammatory mediators in subjects 
with moderate plaque-induced gingivitis. Methods:  This single center, double blinded, 
randomized, controlled trial had two arms: 1) gingivitis subjects using 0.3% 
Triclosan/copolymer/fluoride dentifrice (bid); 2) gingivitis subjects using placebo 
dentifrice (bid). GCF samples were collected on days 1 (pre-dosing, 1, 2, 3 and 6 hours 
post-dosing), 8, 15, 22 and 29 (pre-dosing and 2 hours post-dosing).   Periodontal probing 
exams were performed at baseline (prior to randomization) and day 29. GCF samples 
were analyzed for specific inflammatory biomarkers (PGE2, IL-1β, IL-6, 8-iso-PGF2α 
and RANK-L) using multiplex immunoassay and enzyme-linked immunosorbant assay 
(ELISA) techniques.  Results: A statistically significant suppression of IL-1β at 2 hours 
post-dose on day 1 (p=.0042) was observed in the triclosan group.  In addition, analysis 
showed significant suppression of 8-iso-PGF2α in the triclosan group at day 29 at 2-hours 
post-dose (p=.008).  Further analysis showed a reduction of IL-1β within the triclosan 
group at 1 hour post-dose (p=0.012).  In general, there were consistent elevations of 
inflammatory mediators in the placebo group versus the triclosan group.  Conclusions:  
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Data  indicate that there is short-term in vivo suppression of inflammatory mediators 
associated with periodontal disease after topical application of triclosan in gingivitis 
subjects. 
Introduction 
 The current model of the pathogenesis of periodontal diseases, including 
gingivitis and periodontitis, places emphasis on the bacterial biofilm as the primary 
etiology; however, it is the host inflammatory response, which plays a central role in the 
severity and progression of disease.1  Accordingly, patients with periodontal disease 
exhibit local elevations in inflammatory mediators such as prostaglandin E2 (PGE2) and 
interleukin-1β  (IL-1β) in periodontal tissues and gingival crevicular fluid (GCF).2-4  
Cohort studies and clinical trials indicate that controlling inflammation remains a 
principal strategy for preventing initiation or progression of periodontal diseases.5-9   
Similarly, cumulative evidence from humans and animal models demonstrates that host 
modulatory agents can inhibit local inflammatory mediator expression and improve 
periodontal status independent of any plaque biofilm effects.10-12 
 The majority of preventive and therapeutic approaches for periodontal disease 
focus on reducing or altering biofilm.  Triclosan (2,4, 4΄, trichloro-2΄-hroxydiphenyl 
ether) is a broad spectrum antimicrobial, which has been used for decades in consumer 
products.  It is currently the active agent in a dentifrice (Total; Colgate-Palmolive; 
Piscataway, NJ) approved for the reduction of dental plaque, gingivitis, calculus and 
dental caries in human patients.13-15 Clinical trials have shown, when coupled with a 
copolymer delivery system (polyvinylmethylether maleic acid), that triclosan is highly 
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substantive and provides effective concentration in the oral cavity for 12 hours following 
tooth brushing.16 
 In addition to the substantiated antimicrobial effects of triclosan, recent in vitro 
investigations demonstrate that triclosan also has host modulatory or anti-inflammatory 
effects. Triclosan significantly blocks prostaglandin and IL-1 production in human 
gingival fibroblasts challenged with cytokines.17, 18 Laboratory data also demonstrate that 
the agent inhibits several host enzymes in the arachidonic acid cascade including 
cyclooxygenase-1 and 2, 5-lipoxygenase  and 15-lipoxygenase.19, 20  Triclosan has a 
favorable partial coefficient that allows the agent to readily penetrate epithelial barriers 
like gingiva and skin.20 Transmission electron microscopy using gingival fibroblasts and 
C-labeled-triclosan shows that the agent crosses cell membranes and localizes in the 
nuclei for potential alteration in intracellular signaling pathways related to 
inflammation.21  In addition, triclosan significantly decreases in vivo histamine-induced 
skin inflammation in humans and the allergic patch reaction (APR) to 1% nickel sulfate 
in sensitized subjects.22    
 Despite the proven antiplaque and antigingivitis effects of triclosan in human 
trials, no clinical study to date has investigated the direct anti-inflammatory effects of 
triclosan on local periodontal inflammatory mediators in human subjects.  The primary 
aim of this randomized, controlled clinical trial was to measure and document the in vivo 
local anti-inflammatory effects of topical triclosan in humans with gingivitis. 
Materials and Methods 
Patient Population and Study Design 
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This was a double-blind, randomized, single-center clinical trial conducted at the 
University of North Carolina School of Dentistry.  The protocol was approved by the 
Biomedical Institutional Review Board (IRB), and informed consent was obtained from 
each subject at screening.  Clinical measurements were taken by two examiners who were 
assessed for intra- and inter-examiner reliability prior to study initiation; inter- and intra-
examiner reliability scores were greater than 95% for probing depths within 1mm.   
 Forty-eight subjects meeting inclusion criteria were recruited for this study.  
Subjects were adult males or females, 18 to 60 years old.  Subjects presented with 
generalized, moderate to severe plaque-associated gingivitis, which was defined as 
having at least four teeth with 4-5mm probing depth and 30% of sites bleeding to gentle 
probing.  Subjects presented with at least 20 teeth in the functional dentition excluding 
third molars.  Subjects denied having chronically used triclosan dentifrice within 6 
months prior to enrollment.  Participants also denied having been treated (i.e., two weeks 
or more) with any medication known to affect inflammation or periodontal status (e.g., 
aspirin, nonsteroidal anti-inflammatory drugs, steroids, statins, phenytoin, calcium 
antagonists, cyclosporin and coumadin) within one month of the screening examination. 
All other medications for chronic medical conditions were initiated at least three months 
prior to enrollment.  In addition, subjects did not have gross oral pathology, widespread 
untreated caries, periodontitis (periodontal pocketing > 6 mm at screening), or a history 
of necrotizing periodontal diseases.  Subjects did not currently smoke or report using 
tobacco products within one year of screening.  Finally, no subjects had orthodontic 
appliances or removable partial dentures. 
  The study design was parallel (two arms) and featured a 29-day treatment period. 
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Investigational Treatments, Procedures, and Parameters 
On day 1 of treatment (up to 21 days following screening), vital signs were taken, 
concomitant medication changes were recorded, and an oral soft tissue examination 
performed.   The dental examiner clinically measured the Plaque Index (PI), Gingival 
Index (GI), percent bleeding on probing (BOP), probing depth (PD) and clinical 
attachment level (CAL) for all existing teeth (excluding third molars) at six sites per tooth 
(mesiobuccal, buccal, distobuccal, mesiolingual, lingual, distolingual).23, 24 
 The dental examiner collected 16 GCF samples for inflammatory mediatory 
analyses (Day 1, predosing) from the following sites in four quadrants: mesiobuccal of 
second molars, distobuccal of first molars, mesiobuccal of second premolars and 
distobuccal of first premolars. If one of the listed teeth was missing, the rule was to 
sample from the next anterior (mesial) tooth. Samples were collected onto filter paper 
strips (Pro Flow, Inc., Amityville, NY), and the volume was determined using a Periotron 
8000 (Harco Electronics Limited, Winnipeg, MB, Canada). Samples were wrapped in 
aluminum foil and sealed in cryovials that were labeled and bar-coded with unique 
identifiers for study, subject and specimen identifier. Cryovials were immediately placed 
into liquid nitrogen chair-side and stored at -180°C. 
 Subjects were stratified by gender and randomized into one of two treatment 
arms: 
 Placebo – Control dentifrice containing 0.243% (1100 PPM) sodium fluoride used 
twice daily over 29 days. 
 Experimental - Commercially available dentifrice containing 0.3% triclosan, 2% 
copolymer and 0.243% (1100 PPM) sodium fluoride used twice daily over 29 days.
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 Study dentifrices were packaged in masked, encoded 221g tubes, and one 
randomized tube was given to each subject.  The patient was instructed to administer the 
randomized dentifrice twice daily via the modified Bass brushing technique for three 
minutes.25 In addition, a subject diary was given to the patient to record adverse events or 
changes in medication. 
 A three-minute supervised administration of study dentifrice was performed at 
baseline, and GCF sample collection was repeated at 1, 2, 3, and 6-hours post-dosing. 
 On days 8, 15, 22, 29 subjects returned to the research clinic.  Vital signs and 
changes in medications were recorded.  Oral soft tissue examinations were preformed as 
well.  The dental examiner again collected GCF samples for inflammatory mediator 
analyses (pre-dosing), and the study dentifrice was subject-applied for three-minutes.  
GCF samples were re-collected at two-hours post-dosing. 
 Additionally on Day 29, the examiner re-measured clinical indices.  Study diaries 
were collected, and the returned unused dentifrice was weighed. 
Laboratory Analyses 
 GCF samples were analyzed for specific inflammatory biomarkers using 
multiplex immunoassay and enzyme-linked immunosorbent assay (ELISA) methods 
previously described.2, 3, 26, 27 Four samples were analyzed for each visit, representing 
each quadrant, and the remaining twelve samples were archived.  Biomarkers included 
PGE2, IL-1β, IL-6, 8-iso-prostaglandinF2α (8-iso-PGF2α), and receptor activator of 
nuclear factor kappa B ligand (RANK-L).  The multiplex immunoassay allowed 
simultaneous measurements of IL-1β and IL-6 in each GCF sample.  The remaining 
mediators were analyzed with standard ELISA techniques.  Crevicular fluid 
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concentrations of PGE2, IL-1β, TNF-α, IL-6, RANK-L total are reported in pg/ml, and 8-
iso-PGF2α is reported in mg/l. 
Statistical Plan 
The a priori analytical plan for this trial followed the intent-to-treat principle such 
that all randomized subjects were included in the primary pharmacodynamic 
comparisons.  Patient demographics, clinical parameters and baseline (day 1, pre-dosing) 
mediator levels were compared overall between the groups using t-tests for continuous 
variables and chi-square, Fisher’s exact tests, or analysis of covariance (ANCOVA) for 
categorical variables.   Treatment comparisons for percent inhibition or change from pre-
dosing in GCF were based on analyses using the logarithmic base ten scale to normalize 
the right-tailed skewed distribution of original mediator values.  An ANCOVA was used 
for inter-group comparisons of inflammatory markers for baseline pre-dosing only.  
Paired t-tests were used to examine intra-group differences for each inflammatory 
mediatory pre-dosing and post-dosing for each visit.  Finally, unpaired t-tests were used 
to evaluate inter-group comparisons for changes in GCF concentration at each study visit. 
Results 
Table 1 summarizes the demographics for all subjects enrolled in the trial.  There 
were 48 recruited subjects.  The mean age was 39.9 years old for the placebo group and 
34.0 years for the experimental group.  The gender of the subjects was predominantly 
female with 70.1% in placebo group and 66.6% in the experimental group.  There were 
18 African Americans, 1 Hispanic, and 6 Caucasian subjects in placebo group and 9 
African American, 1 Hispanic, and 14 Caucasian subjects in the experimental group.  The 
Body Mass Index (BMI) was 26±5.7 kg/m2 for placebo group and 25.2±7.0 kg/m2.  There 
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were no significant differences for any demographic criteria between the two groups 
using chi-square tests and t-tests; however, race was trending toward significance 
(p=.09). 
All patients tolerated study dentifrices, and no severe adverse events (AEs) were 
reported. Seventeen non-severe AEs were reported over the course of the trial (nine with 
the placebo dentifrice and eight with the triclosan dentifrice). All AEs were categorized 
as Grade I according to the CTCAE v3.0 scale.28 Overall, AEs were judged as “unlikely 
related” or “not related” to study treatments. The most frequently reported AEs were 
classified as “headache” or “cold-like symptoms” (eight with the placebo dentifrice and 
six with the triclosan dentifrice). One placebo-treated subject reported “tooth sensitivity” 
over the treatment period, and two triclosan-treated subjects reported “oral/gum soreness” 
or a “cold sore”. All AEs resolved by the conclusion of the trial. 
Review of the study diaries and tube weights determined that subjects consistently 
displayed good compliance with bid dosing of dentifrice (data not shown). 
 Baseline and post-treatment (day 29) mean and extent clinical measures are 
reported in Table 2.   The baseline mean PD for placebo group and triclosan group were 
2.52mm and 2.54 respectively.  The baseline mean GI was 1.05 and 1.10 for placebo 
group and triclosan group respectively.  The baseline mean PI was .96 for placebo group 
and .99 for the experimental group.  There were no significant differences in the clinical 
measurements when using an ANCOVA analysis. 
 The mean and median inflammatory mediator values for baseline are reported in 
Table 3 and for the subsequent days in Table 4 and Table 5.  Unpaired t-tests were 
conducted to examine differences between groups for change in GCF concentration 2-
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hours post-dosing for days 1, 8, 15, 22, and 29; they are documented in Figures 1-10.  On 
day one, 2 hours post-dosing, IL-1β was significantly depressed in the triclosan group 
(p=.0042) compared to control.  In addition, 8-iso-PGF2α was statistically lower in the 
test group when percent change in GCF concentration 2-hours post dosing was compared 
to the control at day 29 (p=.008).  In general, there was consistently greater mean percent 
reduction post-dosing in the triclosan group versus placebo although this did not always 
reach statistical significance. 
Paired t-tests on the log transformed inflammatory mediators were used to 
examine within group differences pre-dosing to post-dosing in placebo group and 
triclosan group.  Placebo group had exhibited significant increases for RANK-L between 
pre-dosing at Day 15 (p=.03) and Day 29 (p=.04) at 2 hour post-dosing.  The placebo 
group also had statistically significant increases in levels of PGE2 at Day 2 (p=.01) 
between pre-dosing and post-dosing.  The placebo group also showed an increase in IL-6 
between pre-dosing Day 1 (p=.006) and Day 29 (p=.03) and post-dosing.  There was a 
decrease in the placebo group for IL-1β on Day 2 (p=.005) between pre-dosing and post-
dosing.   The experimental group exhibited an increase for IL-6 (p= .02) on Day 1 
between pre-dosing and post-dosing.  In contrast, the experimental group did have a 
statistically significant decrease in IL-β on day 1 between pre-dosing and 1 hour-post-
dosing.  On average the inflammatory mediators in the placebo group were elevated 
compared to the triclosan group, and this elevation in the placebo group reached 
statistical significance multiple times. 
  
Discussion 
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 The inflammatory markers explored in this study have been implicated in the 
local host inflammatory response associated with periodontal disease 
progression/pathogenesis.  Local elevations of these markers signify a local inflammatory 
response, and reduction of these local inflammatory markers has been associated with 
reduction of disease. 
IL-1β, a cytokine that possesses pro-inflammatory properties is induced by 
microbial challenge, inflammatory agents, and antigens.  29IL-1β  is mainly produced by 
monocytes/macrophages, but is also produced by bone cells and fibroblasts.30, 31  IL-1β 
stimulates T-lymphocytes and lymphokines,  increases production of B-lymphocytes, 
prostaglandin release,  promotes release of matrix metalloproteinases, and promotes 
osteoclast formation and bone resorption.29  IL-1β can also affect neutrophil chemotaxis 
and activation.32   Levels of IL-1β have correlated closely with levels of periodontal 
disease severity, and increased levels of IL-1β may serve as a marker for periodontal 
destruction.33, 34  Recently, Zhong and coworkers demonstrated that elevated levels of 
GCF IL-1β were associated with increased PD and BOP.35  An IL-1 gene cluster has been 
identified that is associated with periodontal disease severity.36 
Similarly, IL-6 is a cytokine that recruits macrophages and activates the acquired 
immune response.  In general, it is released in response to IL-1 or other cytokines as 
opposed to a microbial challenge; therefore, it is considered to represent a second wave 
of inflammatory mediators.  IL-6 can cause tissue destruction by enhancing expression of 
matrix metalloproteinases.37  Offenbacher and coworkers recently showed that patients 
with gingivitis had increased levels of GCF IL-6 compared to healthy controls.26   In 
11 
 
addition, the same group showed that periodontal therapy resulted in a decrease in serum 
IL-6 levels in pregnant subjects with periodontitis.38   
RANK-L, a member of the Tumor Necrosis Factor (TNF) family, is considered a 
marker of bone resorption due to its effects on the upregulation of osteoclasts.  Recent 
clinical investigations have shown an increase in GCF RANK-L in periodontitis patients 
versus healthy patients.39, 40 
PGE2 is a lipid end-product of the arachidonic acid cascade, which is stimulated 
by microbial challenge and is central to the destructive host response in periodontal 
disease.41 PGE2 has been shown to be a potent stimulator of bone resorption, and 
prostanglandin levels are elevated in gingival tissues and crevicular fluid from 
periodontitis patients relative to healthy controls.42 Local concentrations of PGE2 have 
also been shown to be a sensitive marker of attachment loss.43 Recently, elevations in 
PGE2 were positively related to increased PD and increased BOP.35 
8-iso-PGF2α is a prostaglandin-like compound which is generated at the site of a 
free radical attack of the arachidonate component of cell membranes; it can serve as a 
marker for oxidative stress, lipid peroxidation, and low levels of inflammation.  Recently, 
PD greater than or equal to 4mm with third molars was associated with increased serum 
levels of 8-iso-PGF2α cross-sectionally.44  
 Triclosan has shown efficacy against oral bacteria in vitro.45 In addition, clinical 
trials have consistently supported the antiplaque and antigingivitis activity of triclosan.  
Lindhe and coworkers showed a reduction in plaque and gingivitis in subjects over a 6-
month trial when using a triclosan dentifrice.46 Lindhe and coworkers have remarked that 
triclosan appears to reduce gingivitis beyond that anticipated by plaque reduction alone.47 
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For instance, in one trial the investigators observed less clinical inflammation for the 
same amount of plaque in the triclosan-treated group versus gingivitis subjects receiving 
the control dentifrice.  Another clinical trial by Rosling and coworkers showed that 
patients who with destructive periodontitis showed less frequency of deep pockets as well 
as a reduced number of sites with additional probing attachment when using a triclosan 
dentifrice versus placebo.48 These clinical trials suggest that a triclosan dentifrice may 
reduce inflammation independent of the biofilm effects. 
 To explore a reduction in inflammation not concomitant with plaque reduction, 
Modeer and coworkers explored the effect of triclosan on prostaglandin biosynthesis.  
Modeer challenged gingival fibroblasts with IL-1β and a simultaneously applied 
triclosan.  The stimulatory effect of IL-1β on PGE2 formation was reduced in a dose-
dependent manner.  In addition, triclosan reduced the PGE2  production from gingival 
fibroblasts stimulated by TNFα.17  Similarly, Mustafa and coworkers challenged gingival 
fibroblasts with inflammatory cytokines.18  The gingival fibroblasts were treated 
simultaneously with triclosan and TNFα; the stimulation of TNFα on IL-1β production 
was reduced by triclosan.  In situ hybridization showed that the TNFα induced 
expression of IL-1β mRNA was significantly reduced by triclosan; however, the triclosan 
did not reduce mRNA expression or production of the IL-6 challenged by TNFα.  The in 
vitro data from Modeer and Mustafa suggest that triclosan can inhibit the production of 
inflammatory cytokines produced by gingival fibroblasts.  
 Gaffar and coworkers have also explored the anti-inflammatory properties of 
triclosan in vitro.19 Their experiments focused on the enzymes which are important for 
arachidonic acid metabolism:  cyclo-oxygenase 1 (Cox-1), cyclo-oxygenase 2 (Cox-2),  
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5-lipoxygenase, and 15-lipoxygenase.  Their laboratory data demonstrate that the 
triclosan inhibits the following enzymes: Cox-1 and 2 (IC-50=43 and 227 µM 
respectively), 5-lipoxygenase (IC-50=43 µM) and 15-lipoxygenase (IC-50=61 µM).  
These in vitro data suggest that relatively low concentrations of triclosan may be able to 
reduce inflammatory mediators from the arachidonic acid pathway. 
 ANCOVA for GCF inflammatory mediators in the placebo versus triclosan group 
at baseline (pre-dosing, day one) showed no statistical significance differences.  This 
analysis indicates comparability between the levels of local inflammatory mediators prior 
to the intervention with either the triclosan or placebo dentifrice. 
The inter-group comparison, analyzed with unpaired t-tests, revealed that the 
percent change of IL-1β levels between pre-dosing and 2-hours post-dosing was 
significantly reduced in the triclosan group versus the control group on day one.    In 
addition, the percent change of 8-iso-PGF2α between pre-dosing and 2-hours post-dosing 
were statistically significantly reduced in the triclosan group versus the control group on 
day 29.  This data indicates that there was a significant reduction of two of the 
inflammatory markers analyzed two hour post-dosing when comparing the test dentifrice 
with the control dentifrice.  When comparing the change in local inflammatory mediators 
(2 hours post-dose) between the two groups, there was an overall tendency for there to be 
an elevation in the control group versus the triclosan group. 
A paired t-test analysis was performed to see if either of the dentifrices caused 
suppression of the inflammatory markers between pre-dosing and post-dosing.  
Interestingly, the inflammatory markers were elevated in the control group for three 
inflammatory markers (RANKL, PGE2, and IL-6) over 5 different time points when 
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comparing pre-dosing levels to 2 hours post-dosing levels.  In the test group there was an 
elevation of only one inflammatory marker (8-iso-PGF2α ) at one time point when 
comparing pre-dosing levels to 2 hour post-dosing levels.  Application of the test and 
control dentifrices was carried out through a toothbrush and the modified Bass technique.  
It is possible that the process of topical application causes local trauma or bacteremia 
resulting in local increases of inflammatory markers.  The data for our clinical trial 
indicate that were more elevations in local inflammatory mediators (RANKL, PGE2, and 
IL-6) in the control group versus the triclosan group. 
 The paired t-test analysis also showed that there was a statistically significant 
reduction in IL-1β levels in the test group on Day 1 between pre-dose and 1-hour post-
dose.  Although there were reductions of IL-1β levels at each additional visit (Days 8, 15, 
22, 29) between pre-dosing and 2-hours post-dosing, these results did not reach statistical 
significance.  One hour post-dosing measurements were only taken on Day 1.  It is 
possible that topical nature of triclosan application only provides adequate anti-
inflammatory effects for a short period of time.  During these same visits that IL-1β 
levels in the triclosan group were trending toward a decrease after topical application of 
triclosan, 60% of visits (Days 1, 8, 22) in the control group showed a trend towards 
elevation of the IL-1B levels.  Consistently, there was a reduction of local inflammatory 
mediators (especially IL-1β) after dosing with triclosan dentifrice compared to control. 
These clinical data appear to be in agreement with Mustafa and coworkers in vitro 
work, which showed that challenged gingival fibroblasts treated with triclosan reduced 
IL-1β production.21  These clinical data suggest there was a reduction of IL-1β, which 
was significant for a within group comparison at 1 hour post-dosing on day 1.  These data 
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also show that there was a significant difference between the test group and the control 
group at 2 hours post-dosing on day 1.  These data seem to support the in vitro work 
described previously. 
 The local inflammatory mediators studied in this clinical trial have been 
implicated in the progression of destructive periodontal diseases.  Due to the fact that the 
progression of periodontal disease represents a chronic inflammatory response, reduction 
of inflammatory mediators remains a treatment goal.  Triclosan is well-studied 
component of a dentifrice which has been on the market for years with a proven safety 
profile.  The data from this clinical trial indicate statistically significant reductions for IL-
1β after dosing with triclosan compared to control.  In addition, there were consistent 
tendencies for greater elevations of the local inflammatory mediators (RANKL, PGE2, 
and IL-6) in the control group versus triclosan group.  It is important to note that these 
local mediator changes were measured without any significant changes in clinical indices, 
such as PI, GI, or extend PD scores.  Our clinical data suggest support for Mustafa’s in 
vitro work showing reduced production of IL-1β with topical application of triclosan. 
Conclusion 
The data from this RCT suggest short term local inhibition of inflammatory 
mediators, such as IL-1β, following topical application of triclosan dentifrice in gingivitis 
subjects.  These changes occurred independent of any measurable changes in clinical 
plaque or gingivitis scores over a 29-day dosing period; therefore, these changes appear 
to be secondary to direct pharmacodynamic affects of triclosan on host expression of 
these inflammatory mediators locally in GCF in gingivitis subjects. 
 
  
 
 
 
ASSESMENT OF SERUM INFLAMMATORY MEDIATORS 
IN GINGIVITIS POPULATION 
 
ABSTRACT 
Patients with periodontal disease have local and systemic elevations of 
inflammatory mediators.  An objective of this investigation was to explore systemic 
inflammatory levels in gingivitis subjects over the confines of a 4-week clinical trial. 
Methods:  This was a single center, double blinded, randomized, controlled trial with 
two arms: 1) gingivitis subjects using 0.3% Triclosan/copolymer/fluoride dentifrice (bid); 
2) gingivitis subjects using placebo dentifrice (bid).  Serum analyses of inflammatory 
mediators were performed (pre-dosing) at days 1, 8, 15, 22 and 29.   Periodontal probing 
exams were performed at baseline (prior to randomization) and day 29.  Serum 
concentrations of CRP, IL-6 and 8-iso-PGF2α were measured using ELISA techniques.  
Results:  While no inter-group differences in serum biomarkers were detected, data from 
this clinical trial show that levels of CRP were elevated in gingivitis subjects overall.  
CRP mean values ranged from 1.91±1.57(mg/l) to 2.26±1.70(mg/l).  These levels are 
similar to those reported for subjects with end-stage, destructive periodontitis; 
furthermore, the levels in these subjects may confer a moderate risk for future CVD.  
Elevated levels of IL-6 and 8-iso-PGF2α were also in the range that has been reported in 
patients with periodontitis.  Conclusions:  The serum levels of  inflammatory mediators 
were elevated in this trial population of gingivitis subjects.  Gingivitis may represent a 
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critical infection and inflammatory burden that may stimulate systemic inflammatory 
responses. 
 
Introduction 
Despite the widespread acceptance that the primary etiology of periodontal 
disease is a bacterial biofilm, it is often the host inflammatory response that determines 
the course of the disease process.  A bacterial challenge in one patient may result in a 
limited inflammatory response, while another patient may respond with an abnormally 
high inflammatory response.1    Polymorphonuclear neutrophils (PMN), lymphocytes, 
macrophages, and plasma cells lead the local inflammatory response to etiologic gram-
negative bacteria and their products.  Immune cells, as well as fibroblasts, osteoblasts, 
and other cells located in the periodontium, are capable of releasing abnormally high 
amounts of inflammatory mediators in response to the pathogenic biofilm around teeth.  
This robust response may be reflected with local elevations in inflammatory mediators 
such as PGE2 and IL-1β in periodontal tissues and GCF.2-4  
 Patients with periodontal disease not only exhibit increases in local inflammatory 
mediators, but also have increased serum levels of C-reactive Protein (CRP), IL-1, IL-6, 
and other inflammatory markers when compared to healthy controls.49-51  In addition, 
increased levels of serum CRP are associated with elevated levels of infection with 
periodontal pathogens.50   Inflammatory processes have been implemented in many 
pathologic processes in the human body, such as, atherosclerosis, diabetic control, and 
rheumatoid arthritis.52  An elevation of inflammatory mediators triggered by periodontal 
diseases and concomitant bacteremias and endotoxemias could plausibly exacerbate 
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pathologic inflammatory processes elsewhere in the body.53  Systemic inflammation 
from periodontal infection has been linked to increased odds of cardiovascular events, 
delivery of pre-term low birth weight babies, and poor diabetic control.53-55  Thus, 
reducing the systemic inflammatory burden caused by periodontal infection may be an 
important therapeutic or preventive goal for maintaining systemic health.  Interventions 
aimed at reducing the local periodontal infection may also suppress serum inflammatory 
responses.56, 57    
 The majority of the clinical studies conducted to date document serum 
inflammatory mediators in periodontitis subjects.  Currently, there is little evidence on 
these mediators in human subjects with gingivitis.  Due to the possible effect that these 
inflammatory mediators seen locally and systemically may have on other disease 
processes in the body, it is important to document levels in health and at various levels of 
periodontal disease.  The aim of this investigation is to measure and document the levels 
of inflammatory mediators in serum in human gingivitis subjects within the confines of a 
four-week clinical trial of topical triclosan. 
Materials and Methods 
Patient Population and Study Design 
 This was a double-blinded, randomized, single-center clinical trial conducted at 
the University of North Carolina School of Dentistry.  The protocol was approved by the 
Biomedical IRB, and informed consent was obtained from each subject.  Clinical 
measurements were taken by two examiners who were assessed for intra- and inter-
examiner reliability prior to study initiation as described previously.   
 Forty-eight subjects were recruited for this study.  Subjects were adult males or 
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females 18 to 60 years old.  Subjects presented with generalized, moderate plaque-
associated gingivitis which was determined by having at least 4 teeth with 4-5mm 
probing depth and 30% of sites bleeding to gentle probing.  Subjects presented with at 
least 20 teeth in the functional dentition excluding third molars.  In general, subjects were 
medically healthy and were not taking any medications known to affect periodontal 
disease or inflammation.  
  The study design for this double armed phase IV clinical trial featured a 21-day 
screening period and a 29-day treatment period. 
Investigational Procedures, and Parameters 
During screening, subjects gave written informed consent and received oral and 
periodontal evaluations.  Within 21 days of screening examination, subjects initiated the 
treatment period.  On day 1, vital signs were taken, concomitant medication changes were 
recorded, and an oral soft tissue examination performed.  The dental examiner clinically 
measured the PI, GI, percent BOP, PD and CAL for all existing teeth (excluding third 
molars) at six sites per tooth (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, 
distolingual).23, 24 
 There were two treatment groups in this study.  The placebo group used a 
dentifrice containing 0.243% (1100 PPM) sodium fluoride, while the experimental group 
used an approved dentifrice containing 0.3% triclosan, 2% copolymer and 0.243% (1100 
PPM) sodium fluoride (Total; Colgate-Palmolive; Piscataway, NJ).  The patient was 
instructed to administer the randomized dentifrice twice daily via the modified Bass 
brushing technique for three minutes.25   In addition, a subject diary was given to the 
patient to record adverse events or changes in medication. 
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 On days 8, 15, 22, and 29 vital signs and changes in medications were recorded.  
Oral soft tissue examinations were preformed as well.  The dental examiner collected 
whole blood (pre-dosing), and the study dentifrice was applied via a three-minute 
administration.   
 Additionally on Day 29, the examiner clinically re-measured probing 
paramenters, PI, GI, and percent BOP.  Study diaries were collected, and returned 
(unused) dentifrice was weighed. 
 As detailed in the first half of this thesis, 16 GCF samples were also collected 
from each subject (pre-dosing and post-dosing) on days 1, 8, 15, 22, and 29 and stored at 
180 degrees Celsius.  Whole blood (5 ml) was collected from subjects (pre-dosing) for 
analysis of serum mediators. Following collection, blood samples were allowed to clot 
for 2 hours at room temperature before centrifuging (20 minutes at approximately 2000 x 
g).  Serum was decanted into a sample vial that was pre-labeled and bar-coded with 
unique identifiers for study, subject and specimen identifier. Serum vials were stored at -
80°C until analysis. 
Laboratory Analyses 
 Serum concentrations of hsCRP, IL-6 and 8-iso-PGF2α were measured using 
ELISA techniques.58 Briefly, 96-well plates (Linbro, ICN/Flow, Costa Mesa, CA) were 
coated with rabbit antibodies to human CRP, IL-6 and 8-iso-PGF2α (Calbiochem, La 
Jolla, CA) at a concentration of 1 µg/ml. Samples were diluted 1:500 and 1:1000 and 
incubated for three hours and then washed. Biotinylated rabbit antibodies to the same 
human biomarkers (NHS-LC-Biotin reagent, Pierce, Rockford, IL) were added and 
incubated for 2 hours. The plates were washed and incubated overnight with strep-avidin-
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alkaline phosphatase (Zymed, San Francisco, CA). The ELISA was developed with p-
nitrophenylphosphate (Sigma, St. Louis, MO). Each 96-well plate included a full set of 
duplicate standards and appropriate controls. Standard curves for each assay run were 
computed and sample concentrations calculated using the OD value for each sample. 
Standard curves and controls from daily runs were used to generate particular control 
parameters for quality control evaluation. Serum concentrations of CRP, IL-6 and 8-iso-
PGF2α reported in mg/L, pg/ml, and ng/ml respectively.  Similar immunological assays 
were performed for GCF quantification of local inflammatory mediators (PGE2, IL-1β, 
TNF-α, IL-6, RANK-L). 
Statistical Plan 
All subjects randomized and treated were include in the analyses under the intent-
to-treat rule.  Patient demographics, clinical parameters and baseline (day 1, pre-dosing) 
mediator levels were compared overall between the groups using t-tests for continuous 
variables and chi-square, Fisher’s exact tests, or ANCOVA for categorical variables.  
Treatment comparisons for serum biomarker concentrations were based on analyses using 
the log ten base scale and calculation of geometric means.   An ANCOVA was used to 
compare different inflammatory mediators in the placebo group and the experimental 
group at different day time points to look for any significant differences between the two 
groups.  Finally, mean values were calculated for pooled groups for total population 
(n=48). 
Results 
 Table 1 summarizes the demographics for the 48 subjects enrolled in the trial.  
There were no statistical differences for any of the demographic data between the two 
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groups using chi-square and t-tests.  The demographics have been detailed above.  Briefly 
the mean age ranged from 34 -40 years old in the two groups.  Experimental groups were 
predominantly female means ranging from 70.1% in the placebo group and 66.6% in the 
experimental group.  The race of the subjects included African Americans, Hispanics, 
and Caucasians.  Notably, there was an observed trend for a greater number of African 
Americans in the placebo group (p=.09. The Body Mass Index (BMI) was 26±5.7 for the 
placebo group and 25.2±7.0.   
Mean and extent clinical measures are reported in Table 2.   The baseline mean 
PD for placebo group and triclosan group were 2.52mm and 2.54 respectively.  The 
baseline mean GI was 1.05 and 1.10 for groups A and B respectively.  Finally, the 
baseline mean PI was 0.96 for the placebo group and 0.99 for the experimental group.  
There were no significant differences in the clinical measurements when using an 
ANCOVA analysis. 
 The means and medians values for the serum inflammatory mediators measured 
for all subjects, the placebo group and the experimental group are reported in Table 6.   
Overall, the mean values for IL-6 ranged from 1.72±.85(pg/ml) to 2.22±1.50(pg/ml) for 
all subjects over 29 days of the clinical trial.  The mean values for 8-iso-PGF2α ranged 
from 594.9±531.0(ng/ml) to 838.6±452.4(ng/ml) for all subjects.  The CRP mean values 
range from 1.91±1.57(mg/l) to 2.26±1.70(mg/l) for all participants in the trial over the 
course of the four weeks.  An ANCOVA for the log transformed serum markers by visit 
and group showed only a statistical significance for baseline levels of 8-iso-PGF2α 
between control group and triclosan group; the control group was lower at baseline 
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(p=.03).  However, paired t-tests revealed no significant changes within groups over the 
course of the four weeks. 
Since Il-6 and 8-iso-PGF2α were measured both systemically and locally, we 
conducted a Pearson correlation test to asess if there was a correlation between local 
inflammatory markers measured in the GCF and inflammatory markers in the serum.  For 
the two inflammatory markers that were measured in both the GCF and serum, 8-iso-
PGF2α and IL-6, no statistically significant correlation was detected for 8-iso-PGF2α and 
IL-6. 
Discussion 
 The data from this clinical study indicate that serum inflammatory markers may 
be elevated in gingivitis subject.  CRP is an acute phase reactant primarily produced in 
the liver with pro-inflammatory properties.  Accordingly, acute phase reactants can bind 
and activate complement, neutralize pathogens, and stimulate repair and regeneration.59 
CRP has been classified as  a member of the pentraxin family of innate immune response 
proteins.60  CRP has been utilized as a marker for cardiovascular disease (CVD) and the 
marker has been used to assess risk.   Recently, a consensus conference with American 
Heart Association (AHA) and the Centers for Disease Control (CDC) released guidelines 
for CRP levels based on the available evidence on the role of inflammation in the 
pathogenesis of atherosclerosis.61 The consensus reports that subjects with CRP 
concentrations less than 1mg/l are considered to be at low risk.  Patients with 
concentrations in the 1-3mg/l range are assigned a “medium risk” level and those with 
more than 3mg/l in serum CRP are considered “high risk” for future cardiovascular 
disease and events.61 Due to the fact that there is an association between CVD and 
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periodontal disease, which is thought to be based on inflammation, several studies have 
looked at CRP levels in periodontitis patients.  A recent meta-analysis showed that the 
majority of 18 studies demonstrated  elevated CRP levels in periodontitis patients verses 
controls.  Indeed, the majority of the reviewed studies showed CRP levels to be 
>2.1mg/l.59 These levels observed in medically healthy individuals may indicate an 
increased risk of CVD.60   
The mean CRP values in the overall gingivitis population of this clinical trial 
ranged from 1.91±1.57(mg/l) to 2.26±1.70(mg/l).  This evidence suggests that subjects 
who were diagnosed with gingivitis in this clinical trial have CRP levels that would place 
them in a category for moderate risk for future CVD based on the AHA consensus 
report.61  CRP values have been found to be slightly elevated in healthy controls 
previously (patients with minimal or no attachment loss).  A recent review reported that 
healthy controls (no periodontal disease) CRP values ranged from 0.87 – 2.46m.  This 
range can possibly be attributed to BMI fluctuations, CVD, infection, or injury.62 
However, the periodontitis patients in this review reported elevations of 2.40 - 9.12mg/l; 
the elevations in this population versus control may be attributed to inflammation 
associated with periodontitis.62 
 Several clinical studies have evaluated periodontal therapy on CRP levels in 
periodontitis subjects.  D’Aiuto and coworkers conducted a clinical trial on 94 subjects 
with severe generalized periodontitis.  Six months after non-surgical treatment, CRP 
levels were reduced 0.5mg/l from baseline values in this population.56 A second study on 
40 patients showed a range of 0.4 mg/l - 0.6 mg/l reduction in CRP over three follow-up 
visits for subjects in the intensive treatment group (ITG) which consisted of local 
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antibiotics and scaling and root planing (SRP).57  A third study in a population of 60 
severe generalized periodontitis subjects demonstrated a mean reduction of CRP by 
0.5mg/l in the two months after SRP and the ITG reduced mean CRP by 0.8mg/l.63  A 
recent meta-analysis showed an average reduction of 0.5mg/l after periodontal therapy.59  
These trials and meta-analysis indicate that treatment of periodontitis patients with 
aggressive periodontal therapy can lower CRP levels. 
 IL-6 is another inflammatory cytokine that can serve to mediate connective tissue 
destruction by enhancing osteoblast differentiation and activation, and fibroblast 
expression of matrix metalloproteinases.64  IL-6 is an important inflammatory mediator 
that has been shown to induce hepatocytes to produce acute phase reactants such as 
CRP.65  Several studies have reported serum levels of IL-6 in periodontitis patients.  Loos 
and co-workers found that 42% of controls and 53% of periodontitis patients had 
measureable IL-6 levels in serum.49 Like the CRP, the IL-6 levels correlated to the extent 
of disease.  Another group, Buhlin and co-workers, reported elevated IL-6 plasma levels 
versus healthy controls; in addition, there were measurable IL-6 levels in aggressive 
periodontitis patients which correlated with severity of attachment loss.66 
      Mean levels of IL-6 for the gingivitis subjects in the present report ranged from 
1.72±.85 (pg/ml) to 2.22±1.50(pg/ml).  These values are similar to values reported in the 
literature for patients with periodontal disease.  D’Aiuto and co-workers reported median 
baseline values of 1.8pg/ml and values of 1.6pg/ml after SRP.56  Another group, 
Offenbacher and coworkers, reported baseline mean IL-6 values ranging from 0.47-
1.22pg/ml in pregnant subjects with at least one PD greater than 5mm.38  Mendall and 
coworkers reported median values of 1.73pg/ml from a random sample of 198 men aged 
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50-69, for which periodontal status was not documented but that were correlated with 
CVD risk.67  At least one clinical trial has shown a reduction of IL-6 levels with 
periodontal therapy.68  The levels of the gingivitis subjects in the present trial correlate 
closely with the levels in the cohort study reported by Mendall et al.  Future clinical trials 
may look at gingivitis subjects and see if periodontal therapy can reduce IL-6 levels 
which may have implications towards systemic health. 
 8-iso-PGF2α is a member of eicosanoid family called isoprostanes.  Isoprostanes 
are thought to form nonenzymatically by free radical-mediated peroxidation of AA, while 
prostaglandins are produced as a result of COX enzyme activity.69  However, there is 
some evidence that suggests that COX activity may also contribute to isoprostane activity 
in some tissues.69  8-iso-PGF2α has been shown to be elevated in patients with 
atherosclerosis, acute myocardial infarction, Alzheimer’s disease, and has been 
implicated in thrombus development at sites of vascular injury.69  There have been 
reports in the literature of elevated 8-iso-PGF2α  in patients with periodontal disease.  For 
instance, serum levels of 8-iso-PGF2α were associated with an increase in PD greater 
than or equal to 4mm with third molars.44 In addition, Boggess and coworkers showed 
that pregnant subjects with an IgM response to periodontal pathogens combined with 
elevated 8-isoprostane levels resulted in a significantly increased risk for preterm birth.70  
The mean 8-iso-PGF2α values reported by Boggess et al., 121 ng/ml for a cohort of 640 
pregnant subjects, were lower than our reported mean value for 8-iso-PGF2α, which 
ranged from 594.9±531.0(ng/ml) to 838.6±452.4(ng/ml) for all subjects.  The author is 
not aware where other values of 8-iso-PGF2α have been reported in periodontal 
populations. 
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 A Pearson correlation test for levels of 8-iso-PGF2α and IL-6 in the GCF and 
serum showed that there is no correlation between the levels locally and systemically.  
This finding suggests that there is no spill-over of these inflammatory markers from the 
GCF into the serum in gingivitis subjects. 
 The data from this short clinical trial of 48 subjects with gingivitis and no 
professional intervention suggest no change in serum inflammatory levels with the 
treatment twice daily of topical application of triclosan dentifrice or placebo dentifrice.  
The data suggest that serum values for biomarkers like CRP, IL-6 and 8-iso-PGF2α are 
elevated in this gingivitis population comparable to what has been reported in 
periodontitis populations.   Indeed, the levels of CRP that are seen in this population are 
in the range which has been classified as moderate risk for future CVD.  These data 
suggest that gingivitis may impose an inflammatory burden with systemic consequences 
in otherwise medically healthy subjects.   
 
Conclusion 
Serum levels of CRP are elevated in the 48 subjects in this investigation to levels 
that confer moderate risk of future CVD.    Serum IL-6 and 8-iso-PGF2α may also be 
elevated and stable in gingivitis subjects over four weeks.  Gingivitis may represent a 
critical infection/inflammatory burden accompanied by elevated serum responses. 
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Table 1.  
 Demographics 
 Placebo  The experimental group 
Age (years) ± SD 39.9±12.5 34.0±12.1 
Height (inches) 67.5±4.0 67.5±4.0 
Weight (pounds) 171.9±39.9 164.2±49.0 
BMI 26.5±5.7 25.2±7.0 
Male(%) 29.9 33.3 
Female(%) 70.1 66.6 
African American(%) 70.1 38.0 
Hispanic(%) 4.9 3.7 
Caucasian(%) 25.0 58.3 
 
Table 2. 
Mean (Standard Error) Clinical Measures by Day and Group (ANCOVA) 
 Baseline Day 29 
Mean PD   
  Placebo  2.52 (0.04) 2.47 (0.05) 
  Triclosan 2.54 (0.04) 2.55 (0.04) 
    p-value 0.80 0.21 
Extent PD >=4mm (%)   
  Placebo  9.73 (1.07) 8.82 (1.15) 
  Triclosan 9.59 (1.05) 8.70 (1.07) 
    p-value 0.56 0.94 
Mean GI   
  Placebo  1.05 (0.04) 0.99 (0.04) 
  Triclosan 1.10 (0.04) 1.06 (0.04) 
    p-value 0.31 0.20 
Extent GI >=2 (%)   
  Placebo  7.15 (3.13) 8.02 (3.36) 
  Triclosan 12.66 (3.06) 8.66 (3.13) 
    p-value 0.21 0.89 
Mean PI   
  Placebo  0.96 (0.03) 0.93 (0.04) 
  Triclosan 0.99 (0.03) 0.99 (0.03) 
    p-value 0.55 0.30 
Extent PI >=2 (%)   
  Placebo  2.68 (1.52) 2.99 (1.63) 
  Triclosan 5.79 (1.49) 4.47 (1.52) 
    p-value 0.15 0.51 
Extent BOP (%)   
  Placebo  48.1 (1.95) 45.1 (2.09) 
  Triclosan 51.9 (1.91) 44.7 (1.95) 
    p-value 0.31 0.88 
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Table 3. 
GCF Mean (Standard Error) and Median Values Day 1  
 Pre-dosing 1-hour Post-
dosing 
2-hour Post-
dosing 
3-hour Post-
dosing 
6-hour Post-
dosing 
PGE2 (pg/ml)      
Group A      
Mean 252.1(266.3) 459.7(608.2) 700(985.8) 427.8(564.5) 569.5(826.5) 
Median 176.3 252.2 341.2 273.9 193.7 
Group B      
Mean 354.9(446.1) 300.7(297.3) 637.3(965.9) 514.9(514.3) 605.4(819.0) 
Median 201.0 183.3 238.0 293.0 211.7 
IL-1β(pg/ml)      
Group A      
Mean 317.0(291.3) 330.2(354.4) 492.2(545.5) 410.4(396.9) 607.2(783.8) 
Median 197.5 239.0 385.7 272.3 247.8 
Group B      
Mean 414.0(372.0) 257.9(246.8) 326.0(307.7) 304.0(251.1) 643.3(733.1) 
Median 267.4 151.2 201.6 215.3 477.8 
IL-6(pg/ml)      
Group A      
Mean 1.9(4.6) 13.0(29.2) 12.8(23.3) 12.8(30.3) 26.5(81.8) 
Median 0 0 0 0 0 
Group B      
Mean 6.2(16.8) 10.8(19.2) 21.3(46.4) 11.6(22.7) 32.0(65.7) 
Median 0 0 1.9 0 0 
8-iso-PGF2α 
(mg/l) 
     
Group A      
Mean 8.8(16.1) 763449(3.5e6) 9.2(17.0) 5.5(10.1) 65.6(250.8) 
Median 2.4 3.2 3.8 0.04 2.9 
Group B      
Mean 8.0(12.2) 3.2(4.5) 8.1(14.6) 15.8(44.7) 30.2(65.2) 
Median 2.5 2.0 2.0 3.3 5.3 
RANKL(pg/ml)      
Group A      
Mean 5.6(5.0) 4.0(3.5) 4.7(4.0) 4.1(2.9) 5.7(5.0) 
Median 3.5 2.8 3.9 3.3 4.3 
Group B      
Mean 4.9(5.3) 3.1(2.1) 4.2(4.2) 2.8(1.9) 5.7(5.0) 
Median 3.5 2.7 3.7 2.7 2.65 
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Table 4. 
GCF Mean (Standard Error) and Median Values Pre-dosing and Post-dosing for Days 8, 
15, 22, 29.   
                         Day 8                        Day 15                     Day 22                      Day 29 
 
Pre-dosing Post-
dosing 
Pre-dosing Post-
dosing 
Pre-dosing Post-
dosing 
Pre-dosing Post-
dosing 
PGE2(pg/ml)         
Placebo  
        
Mean 452.8 
(445.6) 
527.2 
(803.0) 
213.1 
(165.4) 
506.9 
(646.5) 
345.8 
(373.6) 
263.9 
(362.5) 
386.0 
(511.5) 
565.0 
(756.0) 
Median 353.7 185.1 157.5 203.1 144.3 120.8 137.1 336.8 
Triclosan 
        
Mean 394.6 
(383.8) 
419.9 
(736.1) 
346.9 
(394.3) 
266.6 
(251.0) 
254.6 
(190.1) 
391.8 
(444.0) 
354.4 
(418.3) 
416.5 
(532.3) 
Median 222.8 146.4 237.7 190.4 201.6 218.9 184.8 262.8 
IL-1β 
(pg/ml) 
        
Placebo  
         
Mean 424.8 
(502.0) 
451.4 
(484.8) 
288.3 
(329.5) 
266.5 
(222.5) 
250.6 
(267.8) 
317.0 
(497.3) 
390.3 
(365.5) 
166.9 
(246.5) 
Median 219.5 296.7 196.3 206.1 141.0 160.7 282.3 105.7 
Triclosan 
        
Mean 603.6 
(544.4) 
393.0 
(292.1) 
704.7 
(796.7) 
541.0 
(492.0) 
734.2 
(621.2) 
383.3 
(314.0) 
453.1 
(473.8) 
344.3 
(286.6) 
Median 493.6 350.5 450.5 436.1 584.5 356.3 287.7 319.4 
IL-6(pg/ml) 
        
Placebo  
        
Mean 0.6 
(2.5) 
6.4 
(16.7) 
2.7 
(5.6) 
4.6 
(11.7) 
1.9 
(3.8) 
2.7 
(7.0) 
1.0 
(2.8) 
4.4 
(10.7) 
Median 0 0 0 0 0 0 0 0 
Triclosan 
        
Mean 2.4 
(5.3) 
3.6 
(7.6) 
4.34 
(11.8) 
7.1 
(10.0) 
2.7 
(5.7) 
3.1 
(6.3) 
1.9 
(4.7) 
6.5 
(11.4) 
Median 0 0 0 0 0 0 0 0 
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Table 5. 
GCF Mean and Median Values Pre-dosing and Post-dosing for Days 8, 15, 22, 29  
                            Day 8                        Day 15              Day 22                      Day 29 
 
Pre-dosing Post-dosing Pre-dosing Post-
dosing 
Pre-dosing Post-
dosing 
Pre-dosing Post-dosing 
8-iso-
PGF2α 
(mg/l) 
        
Placebo  
        
Mean 6.6 
(13.4) 
589857.4 
(2.4E6) 
5034.1 
(21914.5) 
15.0 
(24.2) 
12.8 
(21.9) 
12.6 
(23.7) 
6.4 
(9.0) 
251.3 
(1057.8) 
Median .09 4.0 3.6 1.7 3.7 2.3 2.5 3.6 
Triclosan 
        
Mean 27.8 
(73.2) 
16.6 
(21.9) 
7.9 
(13.7) 
5.3 
(8.7) 
10.1 
(14.2) 
4.0 
(6.6) 
17.7 
(39.8) 
7.3 
(13.1) 
Median 6.4 2.7 0.5 .0009 2.4 1.0 3.1 2.1 
RANK-
L(pg/ml) 
        
Placebo  
        
Mean 4.7 
(4.9) 
5.1 
(2.9) 
3.6 
(7.6) 
5.3 
(3.6) 
3.9 
(2.7) 
4.6 
(2.5) 
4.2 
(3.2) 
9.2 
(14.5) 
Median 3.2 5.0 3.5 4.1 2.9 3.6 3.6 4.6 
Triclosan 
        
Mean 9.9 
(22.4) 
8.1 
(14.5) 
4.3 
(2.4) 
4.1 
(2.7) 
6.6 
(7.8) 
5.6 
(7.3) 
3.7 
(3.2) 
4.3 
(3.6) 
Median 4.3 3.8 5.3 3.6 2.7 2.7 2.8 3.6 
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Table 6. 
Mean ±Standard Deviation and Median Serum Marker Values by Day and Group 
 Day 1 Day 8 Day 15 Day 22 Day 29 
Il-6 (pg/ml)      
All      
Mean  1.76±1.60 2.22±1.50 1.90±1.85 1.72±.85 1.92±1.43 
Median 1.25 1.74 1.50 1.47 1.48 
Placebo       
Mean 2.08±2.10 2.38±1.92 2.37±2.51 1.80±0.93 2.12±1.85 
Median 1.42 1.67 1.65 1.47 1.38 
Triclosan      
Mean  1.42±0.69 2.06±0.96 1.42±0.57 1.59±0.74 1.70±0.78 
Median 1.17 1.83 1.27 1.6 1.51 
D8Iso(ng/ml) 
All 
     
Mean 838.6±452.4 646.7±519.4 757.5±472.9 594.9±531.0 600.5±440.2 
Median 867.76 597.76 610.31 594.80 604.74 
Placebo       
Mean 680.2±512.6 573.4±545.2 663.0±476.2 528.1±555.6 645.3±450.6 
Median 605.7 590.9 604.7 589.9 604.2 
Triclosan      
Mean  999.1±321.6 720.1±503.2 852.0±468.8 528.1±555.6 553.1±437.4 
Median 1197.2 600.7 1153.5 604.2 605.7 
CRP(mg/l) 
All 
     
Mean 1.97±1.45 2.26±1.70 1.91±1.57 2.19±1.76 1.99±1.48 
Median 2.05 2.27 1.51 1.69 2.31 
Placebo       
Mean 2.11±1.60 2.46±1.48 1.68±1.48 2.35±1.75 2.01±1.42 
Median 2.05 2.42 1.42 1.99 2.32 
Triclosan      
Mean  1.83±1.30 2.06±1.93 2.13±1.67 1.97±1.82 1.97±1.58 
Median 1.86 1.31 1.55 1.62 2.31 
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Table 7.  
Mean (Standard Error) LOG Serum Markers by Day and Group (ANCOVA) 
 Day1 Day8 Day15 Day22 Day29 
IL6      
  Placebo  0.43 (0.03) 0.48 (0.04) 0.47 (0.04) 0.43 (0.04) 0.45 (0.04) 
  Triclosan 0.37 (0.03) 0.47 (0.04) 0.37 (0.04) 0.40 (0.05) 0.42 (0.04) 
    p-value 0.19 0.85 0.14 0.64 0.59 
D8iso      
  Placebo  5.08 (0.29) 4.56 (0.36) 5.30 (0.36) 4.89 (0.32) 5.32 (0.31) 
  Triclosan 5.97 (0.29) 5.25 (0.36) 5.42 (0.36) 5.21 (0.38) 5.04 (0.32) 
    p-value 0.03 0.18 0.82 0.52 0.53 
CRP      
  Placebo  6.12 (0.11) 6.27 (0.15) 5.96 (0.15) 6.19 (0.13) 6.13 (0.13) 
  Triclosan 5.99 (0.12) 6.02 (0.15) 6.14 (0.15) 6.08 (0.16) 6.07 (0.13) 
    p-value 0.44 0.24 0.40 0.61 0.74 
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Figure 1. Mean Percent Change in GCF IL-1β from Pre-dosing Day 1 
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Figure 2. Mean Percent Change in GCF IL--1β from Pre-dosing Days 8-29 
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Figure 3. Mean Percent Change in GCF IL-6 from Pre-dosing Day 1 
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Figure 4. Mean Percent Change in GCF IL-6 from Pre-dosing Days 8-29 
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Figure 5. Mean Percent Change in GCF RANK-L from Pre-dosing Day 1 
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Figure 6. Mean Percent Change in GCF RANK-L from Pre-dosing Days 8-29 
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Figure 7.  Mean Percent Change in GCF PGE2 from Pre-dosing Day 1 
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Figure 8. Mean Percent Change in GCF PGE2 from Pre-dosing Days 8-29 
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Figure 9. 
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Figure 10.  Mean Percent Change in GCF 8-iso-PGF2α from Pre-dosing Day 1 
-1000
-750
-500
-250
0
250
500
750
1000
% Change from 
Pre-dose to 
Post-dose
8 15 22 29
Days
Mean GCF 8-iso-PGF2alpha levels 
Placebo
Triclosan
*
*p<.05 unpaired t-test
 
 
 
39 
 
References 
1. Offenbacher S. Periodontal diseases: pathogenesis. Ann Periodontol 1996;1(1):821-
878. 
2. Offenbacher S, Farr DH, Goodson JM. Measurement of prostaglandin E in crevicular 
fluid. J Clin Periodontol 1981;8(4):359-367. 
3. Offenbacher S, Odle BM, Gray RC, Van Dyke TE. Crevicular fluid prostaglandin E 
levels as a measure of the periodontal disease status of adult and juvenile periodontitis 
patients. J Periodontal Res 1984;19(1):1-13. 
4. Stashenko P, Jandinski JJ, Fujiyoshi P, Rynar J, Socransky SS. Tissue levels of bone 
resorptive cytokines in periodontal disease. J Periodontol 1991;62(8):504-509. 
5. Lang NP, Adler R, Joss A, Nyman S. Absence of bleeding on probing. An indicator of 
periodontal stability. J Clin Periodontol 1990;17(10):714-721. 
6. Axelsson P, Lindhe J. The significance of maintenance care in the treatment of 
periodontal disease. J Clin Periodontol 1981;8(4):281-294. 
7. Axelsson P, Lindhe J. Effect of controlled oral hygiene procedures on caries and 
periodontal disease in adults. J Clin Periodontol 1978;5(2):133-151. 
8. Axelsson P, Lindhe J, Nystrom B. On the prevention of caries and periodontal disease. 
Results of a 15-year longitudinal study in adults. J Clin Periodontol 1991;18(3):182-189. 
9. Lindhe J, Nyman S. Long-term maintenance of patients treated for advanced 
periodontal disease. J Clin Periodontol 1984;11(8):504-514. 
10. Williams RC, Jeffcoat MK, Howell TH, et al. Altering the progression of human 
alveolar bone loss with the non-steroidal anti-inflammatory drug flurbiprofen. J 
Periodontol 1989;60(9):485-490. 
11. Williams RC, Jeffcoat MK, Kaplan ML, Goldhaber P, Johnson HG, Wechter WJ. 
Flurbiprofen: a potent inhibitor of alveolar bone resorption in beagles. Science 
1985;227(4687):640-642. 
12. Reddy MS, Geurs NC, Gunsolley JC. Periodontal host modulation with 
antiproteinase, anti-inflammatory, and bone-sparing agents. A systematic review. Ann 
Periodontol 2003;8(1):12-37. 
13. Lindhe J, Rosling B, Socransky SS, Volpe AR. The effect of a triclosan-containing 
dentifrice on established plaque and gingivitis. J Clin Periodontol 1993;20(5):327-334. 
14. Schiff T, Cohen S, Volpe AR, Petrone ME. Effects of two fluoride dentifrices 
containing triclosan and a copolymer on calculus formation. Am J Dent 1990;3 Spec 
No:S43-5. 
40 
 
15. Mann J, Vered Y, Babayof I, et al. The comparative anticaries efficacy of a dentifrice 
containing 0.3% triclosan and 2.0% copolymer in a 0.243% sodium fluoride/silica base 
and a dentifrice containing 0.243% sodium fluoride/silica base: a two-year coronal caries 
clinical trial on adults in Israel. J Clin Dent 2001;12(3):71-76. 
16. Afflitto J, Fakhry-Smith S, Gaffar A. Salivary and plaque triclosan levels after 
brushing with a 0.3% triclosan/copolymer/NaF dentifrice. Am J Dent 1989;2 Spec 
No:207-210. 
17. Modeer T, Bengtsson A, Rolla G. Triclosan reduces prostaglandin biosynthesis in 
human gingival fibroblasts challenged with interleukin-1 in vitro. J Clin Periodontol 
1996;23(10):927-933. 
18. Mustafa M, Wondimu B, Ibrahim M, Modeer T. Effect of triclosan on interleukin-1 
beta production in human gingival fibroblasts challenged with tumor necrosis factor 
alpha. Eur J Oral Sci 1998;106(2 Pt 1):637-643. 
19. Gaffar A, Scherl D, Afflitto J, Coleman EJ. The effect of triclosan on mediators of 
gingival inflammation. J Clin Periodontol 1995;22(6):480-484. 
20. Lin YJ, Fung KK, Kong BM, DeSalva SJ. Gingival absorption of triclosan following 
topical mouthrinse application. Am J Dent 1994;7(1):13-16. 
21. Mustafa M, Wondimu B, Hultenby K, Yucel-Lindberg T, Modeer T. Uptake, 
distribution and release of 14C-triclosan in human gingival fibroblasts. J Pharm Sci 
2003;92(8):1648-1653. 
22. Barkvoll P, Rolla G. Triclosan reduces the clinical symptoms of the allergic patch test 
reaction (APR) elicited with 1% nickel sulphate in sensitised patients. J Clin Periodontol 
1995;22(6):485-487. 
23. LOE H, SILNESS J. Periodontal Disease in Pregnancy. I. Prevalence and Severity. 
Acta Odontol Scand 1963;21:533-551. 
24. SILNESS J, LOE H. Periodontal Disease in Pregnancy. Ii. Correlation between Oral 
Hygiene and Periodontal Condtion. Acta Odontol Scand 1964;22:121-135. 
25. Gibson JA, Wade AB. Plaque removal by the Bass and Roll brushing techniques. J 
Periodontol 1977;48(8):456-459. 
26. Offenbacher S, Barros SP, Singer RE, Moss K, Williams RC, Beck JD. Periodontal 
disease at the biofilm-gingival interface. J Periodontol 2007;78(10):1911-1925. 
27. White RP,Jr, Offenbacher S, Phillips C, Haug RH, Blakey GH, Marciani RD. 
Inflammatory mediators and periodontitis in patients with asymptomatic third molars. J 
Oral Maxillofac Surg 2002;60(11):1241-1245. 
41 
 
28. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse 
Events. Version 3.0(Available at: 
http://ctep.cancer.gov.libproxy.lib.unc.edu/forms/CTCAEv3.pdf. 1/21, 2008.) 
29. Tatakis DN. Interleukin-1 and bone metabolism: a review. J Periodontol 1993;64(5 
Suppl):416-431. 
30. Matsuki Y, Yamamoto T, Hara K. Detection of inflammatory cytokine messenger 
RNA (mRNA)-expressing cells in human inflamed gingiva by combined in situ 
hybridization and immunohistochemistry. Immunology 1992;76(1):42-47. 
31. Horowitz MC. Cytokines and estrogen in bone: anti-osteoporotic effects. Science 
1993;260(5108):626-627. 
32. Sauder DN, Mounessa NL, Katz SI, Dinarello CA, Gallin JI. Chemotactic cytokines: 
the role of leukocytic pyrogen and epidermal cell thymocyte-activating factor in 
neutrophil chemotaxis. J Immunol 1984;132(2):828-832. 
33. Masada MP, Persson R, Kenney JS, Lee SW, Page RC, Allison AC. Measurement of 
interleukin-1 alpha and -1 beta in gingival crevicular fluid: implications for the 
pathogenesis of periodontal disease. J Periodontal Res 1990;25(3):156-163. 
34. Ishihara Y, Nishihara T, Kuroyanagi T, et al. Gingival crevicular interleukin-1 and 
interleukin-1 receptor antagonist levels in periodontally healthy and diseased sites. J 
Periodontal Res 1997;32(6):524-529. 
35. Zhong Y, Slade GD, Beck JD, Offenbacher S. Gingival crevicular fluid interleukin-
1beta, prostaglandin E2 and periodontal status in a community population. J Clin 
Periodontol 2007;34(4):285-293. 
36. Kornman KS, Crane A, Wang HY, et al. The interleukin-1 genotype as a severity 
factor in adult periodontal disease. J Clin Periodontol 1997;24(1):72-77. 
37. Kusano K, Miyaura C, Inada M, et al. Regulation of matrix metalloproteinases 
(MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: 
association of MMP induction with bone resorption. Endocrinology 1998;139(3):1338-
1345. 
38. Offenbacher S, Lin D, Strauss R, et al. Effects of periodontal therapy during 
pregnancy on periodontal status, biologic parameters, and pregnancy outcomes: a pilot 
study. J Periodontol 2006;77(12):2011-2024. 
39. Bostanci N, Ilgenli T, Emingil G, et al. Gingival crevicular fluid levels of RANKL 
and OPG in periodontal diseases: implications of their relative ratio. J Clin Periodontol 
2007;34(5):370-376. 
40. Silva N, Dutzan N, Hernandez M, et al. Characterization of progressive periodontal 
lesions in chronic periodontitis patients: levels of chemokines, cytokines, matrix 
42 
 
metalloproteinase-13, periodontal pathogens and inflammatory cells. J Clin Periodontol 
2008;35(3):206-214. 
41. Gemmell E, Marshall RI, Seymour GJ. Cytokines and prostaglandins in immune 
homeostasis and tissue destruction in periodontal disease. Periodontol 2000 1997;14:112-
143. 
42. Goldhaber P, Rabadjija L, Beyer WR, Kornhauser A. Bone resorption in tissue 
culture and its relevance to periodontal disease. J Am Dent Assoc 1973;87(5):1027-1033. 
43. Offenbacher S, Odle BM, Van Dyke TE. The use of crevicular fluid prostaglandin E2 
levels as a predictor of periodontal attachment loss. J Periodontal Res 1986;21(2):101-
112. 
44. Moss KL, Mauriello S, Ruvo AT, Offenbacher S, White RP,Jr, Beck JD. Reliability 
of third molar probing measures and the systemic impact of third molar periodontal 
pathology. J Oral Maxillofac Surg 2006;64(4):652-658. 
45. Bradshaw DJ, Marsh PD, Watson GK, Cummins D. The effects of triclosan and zinc 
citrate, alone and in combination, on a community of oral bacteria grown in vitro. J Dent 
Res 1993;72(1):25-30. 
46. Lindhe J, Rosling B, Socransky SS, Volpe AR. The effect of a triclosan-containing 
dentifrice on established plaque and gingivitis. J Clin Periodontol 1993;20(5):327-334. 
47. Lindhe J, Rosling B, Socransky SS, Volpe AR. The effect of a triclosan-containing 
dentifrice on established plaque and gingivitis. J Clin Periodontol 1993;20(5):327-334. 
48. Rosling B, Wannfors B, Volpe AR, Furuichi Y, Ramberg P, Lindhe J. The use of a 
triclosan/copolymer dentifrice may retard the progression of periodontitis. J Clin 
Periodontol 1997;24(12):873-880. 
49. Loos BG, Craandijk J, Hoek FJ, Wertheim-van Dillen PM, van der Velden U. 
Elevation of systemic markers related to cardiovascular diseases in the peripheral blood 
of periodontitis patients. J Periodontol 2000;71(10):1528-1534. 
50. Noack B, Genco RJ, Trevisan M, Grossi S, Zambon JJ, De Nardin E. Periodontal 
infections contribute to elevated systemic C-reactive protein level. J Periodontol 
2001;72(9):1221-1227. 
51. Slade GD, Offenbacher S, Beck JD, Heiss G, Pankow JS. Acute-phase inflammatory 
response to periodontal disease in the US population. J Dent Res 2000;79(1):49-57. 
52. Mendall MA, Patel P, Asante M, et al. Relation of serum cytokine concentrations to 
cardiovascular risk factors and coronary heart disease. Heart 1997;78(3):273-277. 
53. Offenbacher S, Katz V, Fertik G, et al. Periodontal infection as a possible risk factor 
for preterm low birth weight. J Periodontol 1996;67(10 Suppl):1103-1113. 
43 
 
54. Genco R, Offenbacher S, Beck J. Periodontal disease and cardiovascular disease: 
epidemiology and possible mechanisms. J Am Dent Assoc 2002;133 Suppl:14S-22S. 
55. Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus: a two-way 
relationship. Ann Periodontol 1998;3(1):51-61. 
56. D'Aiuto F, Parkar M, Andreou G, et al. Periodontitis and systemic inflammation: 
control of the local infection is associated with a reduction in serum inflammatory 
markers. J Dent Res 2004;83(2):156-160. 
57. D'Aiuto F, Nibali L, Parkar M, Suvan J, Tonetti MS. Short-term effects of intensive 
periodontal therapy on serum inflammatory markers and cholesterol. J Dent Res 
2005;84(3):269-273. 
58. Ebersole JL, Machen RL, Steffen MJ, Willmann DE. Systemic acute-phase reactants, 
C-reactive protein and haptoglobin, in adult periodontitis. Clin Exp Immunol 
1997;107(2):347-352. 
59. Paraskevas S, Huizinga JD, Loos BG. A systematic review and meta-analyses on C-
reactive protein in relation to periodontitis. J Clin Periodontol 2008;35(4):277-290. 
60. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J 
Intern Med 2002;252(4):283-294. 
61. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and 
cardiovascular disease: application to clinical and public health practice: A statement for 
healthcare professionals from the Centers for Disease Control and Prevention and the 
American Heart Association. Circulation 2003;107(3):499-511. 
62. Loos BG. Systemic markers of inflammation in periodontitis. J Periodontol 
2005;76(11 Suppl):2106-2115. 
63. D'Aiuto F, Parkar M, Nibali L, Suvan J, Lessem J, Tonetti MS. Periodontal infections 
cause changes in traditional and novel cardiovascular risk factors: results from a 
randomized controlled clinical trial. Am Heart J 2006;151(5):977-984. 
64. Kusano K, Miyaura C, Inada M, et al. Regulation of matrix metalloproteinases 
(MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: 
association of MMP induction with bone resorption. Endocrinology 1998;139(3):1338-
1345. 
65. Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum 
amyloid P component and serum amyloid A protein. Immunol Today 1994;15(2):81-88. 
66. Buhlin K, Gustafsson A, Pockley AG, Frostegard J, Klinge B. Risk factors for 
cardiovascular disease in patients with periodontitis. Eur Heart J 2003;24(23):2099-
2107. 
44 
 
67. Mendall MA, Patel P, Asante M, et al. Relation of serum cytokine concentrations to 
cardiovascular risk factors and coronary heart disease. Heart 1997;78(3):273-277. 
68. D'Aiuto F, Ready D, Tonetti MS. Periodontal disease and C-reactive protein-
associated cardiovascular risk. J Periodontal Res 2004;39(4):236-241. 
69. Khasawneh FT, Huang JS, Mir F, Srinivasan S, Tiruppathi C, Le Breton GC. 
Characterization of isoprostane signaling: Evidence for a unique coordination profile of 
8-iso-PGF(2alpha) with the thromboxane A(2) receptor, and activation of a separate 
cAMP-dependent inhibitory pathway in human platelets. Biochem Pharmacol 2008; 
70. Boggess KA, Moss K, Madianos P, Murtha AP, Beck J, Offenbacher S. Fetal immune 
response to oral pathogens and risk of preterm birth. Am J Obstet Gynecol 2005;193(3 Pt 
2):1121-1126. 
 
